ft 03 mar 93 uk compani news dispos limit fison declin continu withdraw product us behind 24 fall pound 124m fison scientif instrument drug group yesterday report pre tax profit year decemb 31 24 per cent pound 162 6m pound 123 6m share fell 7p 222p result suffer continu withdraw two pharmaceut product us impact recess scientif instrument divis would wors pound 23 3m net profit dispos last year loss dispos pound 24 6m trade profit fell 41 per cent pound 197 4m pound 117 4m turnov 4 per cent pound 1 24bn pound 1 28bn figur prepar accord fr 3 last year report pre tax figur pound 190 5m earn per share 20 8p earn per share fell 17 4p 13 9p propos final dividend maintain 5 4p unchang total 8 7p pharmaceut divis report oper profit 38 per cent pound 113 6m pound 71m sale pound 410m pound 427m scientif equip divis profit halv pound 35 1m pound 68 4m sale 5 per cent ahead pound 676 2m pound 644 5m horticultur divis sold gener oper profit pound 11 2m pound 11 5m sale pound 107 8m pound 96 7m gear rose 38 per cent 67 per cent said mr roy thoma financ director dispos brought debt pound 349m pound 200m februari mr patrick egan group chairman said pharmaceut divis margin affect cost overhaul manufactur qualiti control procedur howev complet first six month margin second half improv 11 1 per cent 21 8 per cent sale intal fison best sell asthma drug fell 1 2 per cent pound 192 6m pound 190 3m claim mr cedric scrogg chief execut entir due trade destock us ad plan worldwid prescript intal continu grow satisfactorili 13 per cent tilad group new asthma product shortli launch us gener revenu 22 per cent pound 21 4m pound 26 1m german market particularli strong prescript 22 per cent said mr scrogg point anti inflammatori treatment intal tilad grew 14 per cent compar 11 per cent growth whole asthma market sale opticrom eye product increas 39 per cent pound 31 4m pound 43 7m thank fast growth european contin japan fison continu develop two key new compound tipredan asthma drug remacemid epilepsi treatment tipredan readi registr licens author 1996 remacemid readi 1997 see lex